Effects of Methylglyoxal Bis(guanylhydrazone) on Tumour and Skin Responses to Hyperthermia in Mice

Summary

Effects of methylglyoxal bis(guanylhydrazone) (MGBG) on tumour and skin responses to hyperthermia (42°C) were examined in C3H mice. MGBG (50 mg/kg) was administered intraperitoneally to mice 4 hours before hyperthermic treatment. The tumour (FM3A) growth time was elongated by an amount dependent on the exposure time of treatment at 42°C (60, 90 and 120 min). Pre-treatment of mice with MGBG (50 mg/kg, i.p.) apparently further lengthened the tumour growth time after treatment at 42°C. No significant damage of foot skin was caused by 42°C hyperthermia. Pre-treatment with MGBG did not make the foot skin susceptible to the heating. From these findings, it can be considered that MGBG or related less-toxic compounds may have a clinical advantage for the mild (42°C) hyperthermic treatment in cancer therapy.

• hyperthermia
• methylglyoxal bis(guanylhydrazone)
• FM3A tumour